Erectile dysfunction and cardiovascular disease: a suitable case for treatment and prevention? by Collinson, P
Erectile dysfunction and cardiovascular disease - a suitable case for treatment and 
prevention? 
 
Professor Paul Collinson. 
Departments of Clinical Blood Sciences and Cardiology 
St George’s University Hospitals NHS Foundation Trust and St George’s University of 
London. 
Cranmer Terrace, London SW17 0QT 
paul.collinson@stgeorges.nhs.uk 
 
Keywords 
Erectile dysfunction 
Cardiovascular Disease 
Cardiovascular events 
1344  Words 
 
  
Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection for 
satisfactory sexual performance. The prevalence of ED has been estimated as nearly 40% of 
men > 40 years of age [1] although these figures are contested [2]. ED increases in frequency 
with age and is estimated to affect 15% of men 40-50 years, 45% of men in their 60s and 
70% of men older than 70 years [3]. Successful erection is a complex system involving reflex 
action (peripheral nerves and spinal cord), the limbic system (psychogenic stimuli) and the 
release of nitric oxide. Adequate levels of testosterone are required, hence an intact 
hypothalamo/pituitary/testicular axis. Hence, ED can result from disease or treatment that 
produces hormonal deficiency, neurological impairment, problems with penile blood flow, 
disorders of tissue mechanics, psychological factors or any combination of these. 
Logically, ED secondary to testosterone deficiency should be treated by testosterone 
replacement. Testosterone levels in men decrease with age [4]. Both epidemiological and 
observational studies have demonstrated reduced testosterone is associated with increased 
cardiovascular risk. One meta-analysis showed lower testosterone and higher 17β oestradiol 
as significant risk predictor despite adjustment for age and body mass index [4]. Patients with 
coronary artery disease have been found to have lower testosterone levels than controls and 
there is inverse correlation between testosterone and the incidence of major cardiovascular 
disease (CVD) [4]. A significant negative correlation has been reported between total 
testosterone levels and Framingham risk score [4]. However, it has been pointed out that “It 
is unclear if this is a causal association or due to low testosterone being a biomarker of poor 
health” [4]. Testosterone replacement as a treatment for ED is controversial. Meta-analysis of 
studies has suggested a neutral impact of testosterone replacement on major adverse CVD 
events [4]. However, clinical trials of testosterone replacement and cohort studies of men 
receiving replacement therapy have shown contradictory and diametrically opposed results 
[4]. To date there have been no trials specifically designed to assess replacement in patients 
with CVD. Similarly there is interest in the use of testosterone as a therapeutic option in a 
range of CVD related conditions. The role of testosterone as a risk modifier or a therapeutic 
agent in CVD remains a situation in flux [4]. 
Endothelial dysfunction is one of the first changes in cardiovascular disease. ED and 
cardiovascular disease share many common risk factors including age, hypertension, 
diabetes, insulin resistance, smoking, increased body mass index, cholesterol and low high 
density lipoprotein, metabolic syndrome, sedentary lifestyle and depression [1 3 5]. 
Numerous studies and meta-analyses have confirmed the association between ED and 
coronary artery disease (CAD). ED is associated with asymptomatic CAD [1 3 5]. ED 
precedes CAD and referral for coronary artery disease by periods ranging from 2 to 5 years 
[1]. Compared with controls, patients with ED have a higher risk for total CV events (44%), 
MI (60%) and all-cause mortality (25%) [1]. ED also appears to be a marker of the severity of 
CVD with ED associated with increased risk of CVD mortality with a hazard ratio 1.48 in a 
large meta-analysis of 12 prospective cohort studies [3].  
In the well-characterised multi-ethnic study of atherosclerosis (MESA) study 1862 men free 
of known cardiovascular disease were well-characterised with comprehensive baseline 
subclinical vascular disease phenotyping. ED status was assessed at the fifth visit with a 
standardised questionnaire on ED symptoms [6]. Patients with ED had a higher coronary 
artery calcification score, increased carotid intima medial thickness and plaque score, reduced 
carotid and aortic distensibility and reduced brachial flow mediated dilation. However, out of 
all of these, only coronary artery calcification and carotid plaque score were significantly 
associated with the ED. The authors concluded that subclinical vascular disease is common in 
men who later self-report ED [6]. Assessment of CVD risk factors in men with ED  with or 
without established CVD is a Class IIa Level C recommendation in the joint European 
Society of Cardiology (ESC) 2016 European Guidelines on cardiovascular disease prevention 
in clinical practice[1]. It is less well-established whether ED is a sentinel event for CVD[3] 
but the inclusion of ED symptoms as part of a cardiovascular risk assessment has been 
advocated[5]. However the ESC guidelines consider that there is a gap in the evidence on the 
benefits of routine screening for ED and what is the most effective tool to assess ED is 
unclear. A note of caution is required. Some workers consider that sexual functioning is a 
mirror of overall male health irrespective of cardiovascular risk factors [7]. 
The advent of the phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra™), 
vardenafil (Levitra™) and tadalafil (Cialis™) has transformed the treatment of ED by 
directly targeting endothelial dysfunction. The clinical development of the first in class agent, 
sildenafil was, according to medical urban myth, consequent to an interesting side effect 
noted in early human volunteer studies. This is in fact true.  Sildenafil was originally 
investigated as a potential antihypertensive agent, a role which it maintains in the treatment 
of pulmonary arterial hypertension. Sildenafil produces vasodilatation in vascular beds which 
have high concentrations of PDE5 including the corpus cavernosum and the lungs. Sildenafil 
produces targeted vasodilatation and is a very successful agent for the treatment of ED. It is 
remarkable that this drug is one of the few to have achieved trade name recognition in 
popular culture including being directly mentioned by Sir Michael Caine in a memorable 
scene in the second Austin Powers film “Goldmember”. 
Cardiological interest in PDE5 inhibitors was initially as a safety concern due to the potential 
to interact with nitrates (which remains as a contraindication to their use). Other concerns 
were that cardiovascular events might be precipitated by the physical activity involved post 
administration. One cardiologist recommended anyone contemplating treatment with PDE5 
inhibitors should have a full cardiological assessment prior to administration. In this issue of 
Heart, Andersson and colleagues have performed an analysis of data from the enviable 
Swedish registries looking at the instance of cardiac events in patients receiving treatment for 
ED. They performed a Swedish nation-wide cohort study of all men < 80 years of age 
without prior MI, or cardiac revascularization, hospitalized for MI from 2007 to end 2013. 
They used prescription of PDE5 inhibitors or alprostadil (a prostaglandin), as surrogate for 
the presence of ED and examined how this was related to risk of death, MI, cardiac 
revascularization or heart failure. Those treated with PDE5 inhibitors but not alprostadil had a 
33% lower mortality and 40% lower risk of hospitalization for heart failure. The risk was 
proportionally lower more PDE5 inhibitors were dispensed. 
There are some caveats to this study. Men who receive ED medication are more likely to be 
in a caring relationship, a factor known to reduce CVD risk. In addition those requesting ED 
medication are likely to be healthier, a factor the authors acknowledge and discuss.  Finally, 
the study looks at prescription of ED medication rather than ED itself. This may be strength 
rather than a weakness.  
The first conclusion is that treatment with PDE5 inhibitors appears to be safe. Therefore 
cardiologists may recommend PDE5 inhibitors to their patients (with appropriate clinical 
assessment and medication review). The second is much more intriguing.  PDE5 inhibitors 
may be cardioprotective and a new therapeutic option for treatment or prevention. This is not 
such an outrageous suggestion. Sildenafil has been shown to reduce cardiac infarct size 
following ischaemia/reperfusion injury [8]. The subject has recently been reviewed with the 
suggestion that PDE5 inhibitors may have a role in a range of cardiac and non-cardiac 
conditions [8].  
At this point the findings of Andersson and colleagues must be interpreted with caution but 
PDE5 inhibitors appear to be safe and may even be have a role in therapy for prevention or 
treatment of CVD. This is an area worthy of further study. Perhaps there will be yet another 
serendipitous but useful side effect of sildenafil treatment. The concept of the combined 
preparation of sildenafil and atorvastatin may not be so far-fetched. Improved compliance for 
prevention is likely (and the patient will not roll out of bed at night).  
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